Capital World Investors Takes $26.11 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Capital World Investors purchased a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,016,076 shares of the company's stock, valued at approximately $26,113,000. Capital World Investors owned about 1.10% of NewAmsterdam Pharma at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. National Bank of Canada FI bought a new position in shares of NewAmsterdam Pharma during the 4th quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $80,000. KLP Kapitalforvaltning AS bought a new position in shares of NewAmsterdam Pharma in the 4th quarter worth $154,000. Barclays PLC grew its position in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Finally, HB Wealth Management LLC bought a new stake in NewAmsterdam Pharma during the 4th quarter valued at $224,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Stock Up 0.3 %

NASDAQ NAMS traded up $0.05 during trading hours on Friday, reaching $17.52. 345,323 shares of the company were exchanged, compared to its average volume of 590,491. The stock has a market capitalization of $1.92 billion, a P/E ratio of -6.74 and a beta of -0.01. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29. The business's 50 day simple moving average is $19.66 and its 200-day simple moving average is $21.20.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, Director James N. Topper bought 1,135 shares of the business's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the purchase, the director now directly owns 3,013,569 shares in the company, valued at $67,775,166.81. This trade represents a 0.04 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. The trade was a 90.91 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 19.50% of the company's stock.

Wall Street Analysts Forecast Growth

NAMS has been the topic of a number of analyst reports. Scotiabank upped their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research note on Monday, March 3rd. HC Wainwright reissued a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Buy" and an average price target of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.